In various animal models of traumatic brain injury, acute treatments quiet inflammation and preserve neurons and their myelin sheaths.
Researchers at this year’s SfN meeting detailed different strategies and outcomes of passive and active vaccines.
The leaders of two large European trials report that promoting cardiac health, exercise, and mental activity helped maintained cognition in older adults.
Forget transgenics for a moment. Large collections of inbred and outbred mice could be an untapped treasure trove for Alzheimer’s researchers.
At CTAD, investigational Phase 1 drugs include a repackaged and a new anti-amyloid, a tau vaccine, and a repurposed cancer drug.
At CTAD, a handful of candidate therapies were reported to have flamed out in Phase 2. They were unable to show efficacy. A new antipsychotic is entering the ring.
Several therapeutic approaches in Phase 3 reported updates at the CTAD conference earlier this month in Barcelona. Read about levetiracetam, deep brain stimulation, and scyllo-inositol.
The CTAD conference featured discussion among many scientists of how to measure a drug’s effect in pre-dementia patients who are so mildly impaired that established tools have trouble picking up improvement. Better cognitive tools are needed.
Both antibodies might be working, experts say, but the latest data released at the CTAD conference remain tantalizingly unclear. Trialists urgently need progression predictors and better outcome measures.
In a process known as repeat-associated non-ATG translation, neurons and glia make alanine, serine, cysteine, and leucine chains from the huntingtin gene.
Paralyzed mice recovered grip strength and balance when researchers turned off TDP-43.
Meet RBM45. This RNA-binding protein and relatively new player in the ALS field associates with stress-induced structures in the cytoplasm and nucleus.
Scientists say treatments to muzzle faulty genes are making some headway.
Scientists at SfN offer alternate views of Bin1 biology.
Scientists start to unravel role played by genetic risk variants.